Enhancing effects of adjuvanted 2009 pandemic H1N1 influenza A vaccine on memory B-cell responses in HIV-infected individuals

AIDS

Volumn 25, Issue 3, 2011, Pages 295-302

  Ho, Jason ^a   Moir, Susan ^a   Wang, Wei ^a   Posada, Jacqueline G ^a   Gu, Wenjuan ^b   Rehman, Muhammad T ^b   Dewar, Robin ^b   Kovacs, Colin ^c   Sneller, Michael C ^a   Chun, Tae Wook ^a   Follmann, Dean A ^b   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b SAIC FREDERICK INC   (United States)

^c MAPLE LEAF MEDICAL CLINIC   (Canada)

Author keywords

adjuvants; antibody response; HIV infection; memory B cell response; pandemic influenza; vaccination

Indexed keywords

ANTIVIRUS AGENT; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE;

ADJUSTMENT; ADULT; AGE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CANADA; CD4+ T LYMPHOCYTE; CELL COUNT; CONTROLLED STUDY; GENDER; HEALTH; HEMAGGLUTINATION INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INFLUENZA A (H1N1); INFLUENZA VIRUS A H1N1; LOW DRUG DOSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MEMORY CELL; OUTPATIENT DEPARTMENT; PANDEMIC; PLANT LEAF; PRIORITY JOURNAL; STANDARD; UNITED STATES; VACCINATION; VIROTHERAPY;

ADJUVANTS, IMMUNOLOGIC; ADULT; B-LYMPHOCYTES; CD4 LYMPHOCYTE COUNT; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MARYLAND; ONTARIO; PANDEMICS; VACCINATION;

EID: 79551575873     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328342328b     Document Type: Article

References (34)

1. National Center for Immunization and Respiratory Diseases, CDC; Centers for Disease Control and Prevention (CDC). Use of influenza A (H1N1) 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1-8.
2. Lin JC, Nichol KL. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001; 161:441-446.
3. Neuzil KM, Reed GW, Mitchel EF Jr, Griffin MR. Influenzaassociated morbidity and mortality in young and middle-aged women. JAMA 1999; 281:901-907.
4. Radwan HM, Cheeseman SH, Lai KK, Ellison IR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis 2000; 31: 604-606.
5. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990; 98: 33-37.
6. Nichol KL. Efficacy and effectiveness of influenza vaccination. Vaccine 2008; 26 (Suppl 4):D17-D22.
7. Leroux-Roels I, Borkowski A, Vanwolleghem T, Drame M, Clement F, Hons E, et al. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370:580-589.
8. Roman F, Vaman T, Gerlach B, Markendorf A, Gillard P, Devaster JM. Immunogenicity and safety in adults of one dose of influenza A H1N1 v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine 2010; 28:1740-1745.
9. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, et al. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults. J Infect Dis 2008; 198:642-649.
10. Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, et al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-2435.
11. Liang XF, Wang HQ, Wang JZ, Fang HH, Wu J, Zhu FC, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2010; 375: 56-66.
12. Cooper CL, Angel JB, Seguin I, Davis HL, Cameron DW. CPG 7909 adjuvant plus hepatitis B virus vaccination in HIVinfected adults achieves long-term seroprotection for up to 5 years. Clin Infect Dis 2008; 46:1310-1314.
13. Iorio AM, Francisci D, Camilloni B, Stagni G, De Martino M, Toneatto D, et al. Antibody responses and HIV-1 viral load in HIV-1-seropositive subjects immunised with either the MF59- adjuvanted influenza vaccine or a conventional nonadjuvanted subunit vaccine during highly active antiretroviral therapy. Vaccine 2003; 21:3629-3637.
14. Malaspina A, Moir S, Orsega SM, Vasquez J, Miller NJ, Donoghue ET, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005; 191:1442-1450.
15. Nelson KE, Clements ML, Miotti P, Cohn S, Polk BF. The influence of human immunodeficiency virus (HIV) infection on antibody responses to influenza vaccines. Ann Intern Med 1988; 109:383-388.
16. Amendola A, Boschini A, Colzani D, Anselmi G, Oltolina A, Zucconi R, et al. Influenza vaccination of HIV-1-positive and HIV-1-negative former intravenous drug users. J Med Virol 2001; 65:644-648.
17. Kroon FP, van Dissel JT, de Jong JC, Zwinderman K, van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000; 18:3040-3049.
18. Kroon FP, Rimmelzwaan GF, Roos MT, Osterhaus AD, Hamann D, Miedema F, et al. Restored humoral immune response to influenza vaccination in HIV-infected adults treated with highly active antiretroviral therapy. AIDS 1998; 12:F217- 223.
19. Evison J, Farese S, Seitz M, Uehlinger DE, Furrer H, Muhlemann K. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis 2009; 48:1402-1412.
20. Tebas P, Frank I, Lewis M, Quinn J, Zifchak L, Thomas A, et al. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS 2010; 14:2184-2192. doi:10.1097/QAD. 1090b1013e32833c32836d32835c.
21. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010; 17:1055-1065.
22. Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol 2009; 21:298-304.
23. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. Immunity 2007; 27:384-392.
24. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357:1903-1915.
25. Dowdle W, Kendal A, Noble G, editors. Influenza viruses, 5th ed. Washington, DC: American Public Health Association; 1979.
26. Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:1100-1108.
27. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009; 9:235-245.
28. Moir S, Ho J, Malaspina A, Wang W, DiPoto AC, O'Shea MA, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIVinfected viremic individuals. J Exp Med 2008; 205:1797-1805.
29. Moir S, Buckner CM, Ho J, Wang W, Chen J, Waldner AJ, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010 [Epub ahead of print].
30. Durando P, Fenoglio D, Boschini A, Ansaldi F, Icardi G, Sticchi L, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol 2008; 15:253-259.
31. Mbow ML, De Gregorio E, ValianteNM, Rappuoli R. Newadjuvants for human vaccines. CurrOpin Immunol 2010; 22:411-416.
32. Bickel M, Wieters I, Khaykin P, Nisius G, Haberl A, Stephan C, et al. Low rate of seroconversion after vaccination with a split virion, adjuvanted pandemic H1N1 influenza vaccine in HIV- 1-infected patients. AIDS 2010; 24:F31-F35.
33. Allwinn R, Geiler J, Berger A, Cinatl J, Doerr HW. Determination of serum antibodies against swine-origin influenza A virus H1N1/09 by immunofluorescence, haemagglutination inhibition, and by neutralization tests: how is the prevalence rate of protecting antibodies in humans? Med Microbiol Immunol 2010; 199:117-121.
34. Baer J, Santiago F, Yang H, Wu H, Holden-Wiltse J, Treanor J, et al. B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant. Vaccine 2010; 28:907-915.